Stifel Financial Corp Nektar Therapeutics Transaction History

Stifel Financial Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 13, 2019	SELL	$16.91 - $36.27 $175,018 - $375,394	-10,350 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$31.0 - $36.3 $5,487 - $6,425	177 Added 1.74%	10,350 $369,000
Q1 2019 May 14, 2019	BUY	$31.58 - $46.35 $77,528 - $113,789	2,455 Added 31.81%	10,173 $341,000
Q4 2018 Feb 13, 2019	SELL	$30.43 - $56.65 $180,936 - $336,840	-5,946 Reduced 43.52%	7,718 $253,000
Q3 2018 Nov 13, 2018	SELL	$46.46 - $68.49 $6,225 - $9,177	-134 Reduced 0.97%	13,664 $833,000

Q2 2018 Aug 14, 2018	SELL	$46.25 - $104.45 $108,178 - $244,308	-2,339 Reduced 14.49%	13,798 $674,000
Q1 2018 May 11, 2018	SELL	$57.4 - $108.44 $547,194 - $1.03 Million	-9,533 Reduced 37.14%	16,137 $1.72 Million
Q4 2017 Feb 14, 2018	SELL	$23.02 - $60.5 $22,697 - $59,653	-986 Reduced 3.7%	25,670 $1.53 Million
Q3 2017 Nov 13, 2017	BUY	$17.79 - $24.0 $474,210 - $639,744	26,656	26,656 $0

126

109M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $259M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Stifel Financial Corp with notifications on news.